Hormonal
Administration of GLP-1 receptor agonists (semaglutide 2.4 mg weekly or liraglutide 3.0 mg daily) combined with lifestyle interventions significantly reduces body weight and modulates gut microbiota composition in adults with obesity.
If you have obesity, GLP-1 medications like semaglutide (2.4 mg weekly) or liraglutide (3.0 mg daily) are highly effective for weight loss when combined with lifestyle changes. They work by mimicking hormones that regulate blood sugar and gut health, leading to significant weight reduction and improved metabolic markers.
a semaglutida subcutânea uma vez por semana, em comparação com a liraglutida subcutânea uma vez ao dia, adicionada ao aconselhamento sobre dieta e atividade física, resultou em perda de peso significativamente maior em 68 semanas. A alteração média no IMC desde o início até a semana 68 foi de -16,1% com semaglutida e 0,6% com placebo.
Why this rating
Based on multiple randomized controlled trials (RCTs) cited in the review, though it is a review paper itself.
Source
CONSUMO DE PREBIÓTICOS, PROBIÓTICOS E TERAPIA FAMACOLÓGICA E SUA RELAÇÃO COM A MODULAÇÃO INTESTINAL NO TRATAMENTO DA OBESIDADE: UMA REVISÃO DA LITERATURA
Gabriela Cristina Uebel et al. · Revista Contemporânea · 2023
DOI 10.56083/rcv3n12-093
More from this paper
- Supplementation with specific probiotics (e.g., Lactobacillus gasseri SBT2055, Lactobacillus curvatus HY7601, and Lactobacillus plantarum KY1032) reduces abdominal adiposity and body weight in overweight or obese individuals.Moderate
- Prebiotic supplementation (inulin, oligofructose, galactooligosaccharides) modulates gut microbiota (increasing Bifidobacterium) and improves metabolic markers in overweight or obese individuals.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →